Genomics of Hairy Cell Leukemia

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• Hairy cell leukemia (HCL) is a chronic B-cell neoplasm initially responsive to purine analogs but prone to relapse.
• The genetic basis of HCL was recently identified as a BRAF-V600E mutation, present in nearly all patients.
• This mutation aberrantly activates the RAF-MEK-ERK pathway, influencing HCL's biology and characteristics.

Purpose of the Study:

• To elucidate the role of BRAF-V600E in HCL pathogenesis and its potential as a diagnostic marker and therapeutic target.
• To evaluate the efficacy of BRAF inhibitors in patients with relapsed or refractory HCL.

Main Methods:

• Genetic analysis to identify the BRAF-V600E mutation in HCL and related B-cell neoplasms.
• Ex vivo studies of leukemic cells with BRAF inhibitors.
• Clinical trials using the BRAF inhibitor vemurafenib in relapsed/refractory HCL patients.

Main Results:

• BRAF-V600E is a near-universal, clonal mutation in HCL, distinguishing it from HCL-like neoplasms.
• BRAF inhibitors induce apoptosis in HCL cells ex vivo.
• Vemurafenib demonstrated a ~100% response rate, with 35-42% complete remission, in heavily pretreated HCL patients without myelotoxicity.

Conclusions:

• BRAF-V600E is the defining genetic event in HCL and a valuable diagnostic marker.
• Targeting BRAF-V600E with inhibitors like vemurafenib offers a highly effective, non-myelotoxic treatment option for relapsed/refractory HCL.
• Future research should focus on optimizing BRAF inhibitor therapy and exploring novel combinations to improve eradication rates.